Corvus Pharmaceuticals, Inc. 8-K

What Happened

• Corvus Pharmaceuticals (CRVS) announced final randomized, blinded, placebo‑controlled Phase 1 results for soquelitinib in moderate‑to‑severe atopic dermatitis on May 14, 2026. The study enrolled 72 patients and tested multiple dosing regimens, including 200 mg twice daily (the highest dose tested). The company furnished a press release as Exhibit 99.1 to the 8‑K.

Key Details

• Trial design: 72 patients total; cohorts 1–3 (16 patients each) randomized 3:1 to 28‑day regimens (100 mg BID, 200 mg QD, 200 mg BID) vs placebo; cohort 4 (24 patients) randomized 1:1 to 56 days of 200 mg BID vs placebo. Follow‑up: 30 days post‑treatment (cohort 3 had 90‑day follow‑up).
• Safety: Adverse events occurred in 41.7% of soquelitinib and 41.7% of placebo patients; all reported events were Grade 1–2, with no dose modifications, no severe/serious adverse events, and no significant lab abnormalities.
• Efficacy (200 mg BID): Cohort 3 (4 weeks): 50% achieved EASI‑75, 8% EASI‑90, 25% IGA 0/1. Cohort 4 (8 weeks): 75% EASI‑75, 25% EASI‑90, 33% IGA 0/1. Disease control was maintained through the drug‑free follow‑up (no rebound or rescue meds reported).
• Biomarkers: Peripheral blood studies showed dose‑dependent reductions in Th2/Th17 activity and cytokines (IL‑4, IL‑5, IL‑13), increased persistent Treg cells, increased SOCS3, and reductions in JAK1/STAT6 — findings consistent with Corvus’s ITK‑targeted mechanism for soquelitinib.

Why It Matters

• These Phase 1 results demonstrate safety and dose‑related efficacy signals for soquelitinib, including durable responses after stopping treatment at the 200 mg BID dose—an outcome the company highlights as differentiating from some approved systemic therapies that can show rebound.
• For investors, the data support continued development of soquelitinib in atopic dermatitis and provide clinical and mechanistic evidence to inform next steps (larger trials). The filing also contains forward‑looking statements and references risks (including the need for further trials and regulatory uncertainty) and notes reference to the company’s other filings regarding financing and runway.